-transparent.png){kind=logo}
Therapeutic drug monitoring has been an integral part of the clinical investigations of cyclosporin G (OG37-325 CsG), an analogue of cyclosporin A (CsA). In general, analytic approaches used for monitoring of CsA have been used for the measurement of CsG. However, the validity of this approach may be questioned, as there are significant differences between the two drugs in the areas of blood distribution, pharmacokinetics, steady-state concentration of metabolites, and biases with the various immunoassays adapted for measurement of the drug. Based on the above, it is not appropriate to assume that the therapeutic drug monitoring protocols previously established for CsA are applicable to CsG. The latter drug should be treated as a new compound, with the development of independent therapeutic monitoring guidelines. Similar approaches should be used for other immunosuppressive drugs.
R W Yatscoff, and
L Langman, and
D F LeGatt
May 2003,
The Clinical biochemist. Reviews,
R W Yatscoff, and
L Langman, and
D F LeGatt
January 1989,
Clinical pharmacokinetics,
R W Yatscoff, and
L Langman, and
D F LeGatt
December 1995,
Therapeutic drug monitoring,
R W Yatscoff, and
L Langman, and
D F LeGatt
January 1991,
European journal of clinical pharmacology,
R W Yatscoff, and
L Langman, and
D F LeGatt
December 1992,
BMJ (Clinical research ed.),
R W Yatscoff, and
L Langman, and
D F LeGatt
April 1999,
Clinical transplantation,
R W Yatscoff, and
L Langman, and
D F LeGatt
April 1997,
Therapeutic drug monitoring,
R W Yatscoff, and
L Langman, and
D F LeGatt
December 1994,
Therapeutic drug monitoring,
R W Yatscoff, and
L Langman, and
D F LeGatt
January 2005,
British journal of clinical pharmacology,
R W Yatscoff, and
L Langman, and
D F LeGatt
April 2000,
European journal of clinical pharmacology,
